Klivira
Request demo

Eylea Prior Authorization for Cardiology: Navigating Complex Patient Journeys

While Eylea's primary indications are ophthalmological, managing **Eylea prior authorization for cardiology** patients with comorbidities like diabetes requires integrated, system-wide PA strategies.

Revenue cycle and prior authorization teams in cardiology often encounter complex patient profiles, including those requiring specialty drugs for non-cardiac conditions. Efficiently managing these diverse prior authorization workflows, particularly for buy-and-bill medications like Eylea, is crucial for financial health and patient access within a comprehensive health system.

Eylea (Aflibercept) in the Context of Cardiology Patient Care

Eylea (aflibercept) is an anti-VEGF intravitreal injection primarily indicated for ophthalmological conditions such as wet age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion. While these are not primary cardiac conditions, cardiologists frequently manage patients with significant comorbidities like diabetes, which is a leading cause of DME. This overlap means cardiology teams are part of a larger patient care ecosystem where such specialty drugs are vital.

The Intersecting Needs: Why Cardiology Teams Encounter Eylea PA

For health systems, the administrative burden of prior authorization extends beyond a single specialty. Cardiology departments, while not directly prescribing Eylea, operate within a framework where patients may require this medication from ophthalmology. Efficient management of these "buy-and-bill" specialty drugs, including their prior authorization, impacts the entire revenue cycle. This necessitates a system-wide approach to PA that can track and support complex patient journeys across multiple departments.

Streamlining Prior Authorization for Specialty Buy-and-Bill Drugs

  • Verification of specific indication (e.g., wet AMD, DME) against payer policy.
  • Documentation of clinical findings supporting medical necessity (e.g., visual acuity, retinal imaging).
  • Coordination between prescribing specialty (Ophthalmology) and billing/revenue cycle teams.
  • Management of drug acquisition and inventory for buy-and-bill medications.
  • Adherence to specific payer requirements, which may include step therapy or preferred drug lists.
  • Expedited pathways for urgent cases, where applicable, though less common for Eylea.

Optimizing Specialty Drug Prior Authorization Across Departments

Managing prior authorizations for specialty drugs like Eylea within a large health system requires robust, integrated solutions. Cardiology, known for its high PA volume in areas like advanced imaging and interventional procedures, benefits from a platform that can handle diverse PA workflows. Klivira provides a centralized system to manage these complex requests, reducing manual effort and improving turnaround times for all specialty medications.

Klivira's Role in Integrated Prior Authorization Management

Klivira's platform is designed to automate prior authorization processes for high-volume and complex specialty drugs, including those with buy-and-bill workflows. By integrating with EMRs and connecting to payer portals and specialty benefit-management vendors, Klivira ensures that all relevant documentation is submitted efficiently. This comprehensive approach supports health systems in managing the administrative complexities of drugs like Eylea, even when prescribed by a different specialty, contributing to overall revenue integrity.

Frequently asked questions

Why would a cardiology department be concerned with Eylea prior authorization?

While cardiologists do not typically prescribe Eylea, they often manage patients with comorbidities like diabetes, a primary indication for Eylea in ophthalmology. Health systems require efficient, system-wide prior authorization processes for all specialty drugs, including buy-and-bill medications like Eylea, to ensure seamless patient care and optimized revenue cycle management across departments.

Does Klivira's platform integrate with EMRs to manage specialty drug prior authorizations?

Yes, Klivira integrates directly with major EMR systems to streamline prior authorization workflows for specialty drugs. This integration enables automated data extraction, submission, and status tracking, reducing manual data entry and improving efficiency for medications like Eylea across various clinical specialties.

How does Klivira handle the unique aspects of buy-and-bill drugs like Eylea?

Klivira's platform is built to support the complex workflows associated with buy-and-bill specialty drugs. It automates the submission of necessary documentation, tracks authorization status, and facilitates coordination between clinical, pharmacy, and billing teams, ensuring compliance with payer requirements and optimizing the revenue cycle for these high-cost medications.

What are common documentation requirements for anti-VEGF drugs like Eylea?

Common documentation requirements for anti-VEGF drugs include confirmation of diagnosis (e.g., wet AMD, DME, retinal vein occlusion), visual acuity measurements, retinal imaging (e.g., OCT, fluorescein angiography), and previous treatment history. Payers often require specific clinical criteria to be met for approval, aligning with established clinical guidelines.

Can Klivira assist with prior authorization for specialty cardiovascular drugs?

Absolutely. Klivira specializes in automating prior authorizations for a wide range of specialty drugs, including high-volume cardiovascular medications like PCSK9 inhibitors, sacubitril/valsartan (Entresto), and SGLT2 inhibitors for heart failure indications. Our platform handles payer-specific step-therapy logic and complex documentation requirements common in cardiology.

Related coverage

Other eylea prior authorization by payer

Other eylea prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo